Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
36
PMN Quote, Financials, Valuation and Earnings
Last price:
$0.48
Seasonality move
:
-4.8%
Day range:
$0.40 - $0.46
52-week range:
$0.38 - $2.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.55x
Volume:
1.3M
Avg. volume:
3.5M
1-year change:
-79.45%
Market cap:
$14.7M
Revenue:
--
EPS (TTM):
-$0.05
Analysts' Opinion
-
Consensus RatingProMIS Neurosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.34, ProMIS Neurosciences has an estimated upside of 1087.17% from its current price of $0.45.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.07 representing -581.33% downside risk from its current price of $0.45.
Fair Value
-
According to the consensus of 2 analysts, ProMIS Neurosciences has 1087.17% upside to fair value with a price target of $5.34 per share.
PMN vs. S&P 500
-
Over the past 5 trading days, ProMIS Neurosciences has overperformed the S&P 500 by 14.69% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ProMIS Neurosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ProMIS Neurosciences has grown year-over-year revenues for 1 quarter straight. In the most recent quarter ProMIS Neurosciences reported revenues of --.
Earnings Growth
-
ProMIS Neurosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ProMIS Neurosciences reported earnings per share of -$0.21.
Enterprise value:
6.3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
1.40x
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.29x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
1.40x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$24.4M | -$13M | -$20.6M | -$3.7M | -$7.5M | |
| EBITDA | -$20.8M | -$11.6M | -$933.9K | -$3.6M | -$7.3M | |
| Diluted EPS | -$2.70 | -$0.84 | -$0.05 | -$0.19 | -$0.21 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7.3M | $14.4M | $4.4M | $3.5M | $13.6M | |
| Total Assets | $7.4M | $14.4M | $4.4M | $3.5M | $13.6M | |
| Current Liabilities | $1.8M | $1.4M | $8.7M | $2.6M | $4.1M | |
| Total Liabilities | $14.3M | $10.7M | $10.6M | $3.5M | $4.2M | |
| Total Equity | -$6.9M | $3.7M | -$6.2M | $77.1K | $9.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$16.2M | -$18.6M | -$21.8M | -$10.3M | -$4.9M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | $17.9M | $27.7M | $190.3K | -- | |
| Free Cash Flow | -$16.2M | -$18.6M | -$21.8M | -$10.3M | -$4.9M | |
PMN
Sector
Market Cap
$14.7M
$34.4M
Price % of 52-Week High
20.27%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-79.45%
-37.36%
Beta (5-Year)
-0.097
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.43
200-day SMA
Sell
Level
$0.79
Bollinger Bands (100)
Sell
Level
0.47 - 0.69
Chaikin Money Flow
Sell
Level
-75.3M
20-day SMA
Sell
Level
$0.46
Relative Strength Index (RSI14)
Sell
Level
47.58
ADX Line
Buy
Level
35.96
Williams %R
Buy
Level
-91.954
50-day SMA
Sell
Level
$0.49
MACD (12, 26)
Buy
Level
0.12
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
95.5M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
Stock Forecast FAQ
In the current month, PMN has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PMN average analyst price target in the past 3 months is $5.34.
-
Where Will ProMIS Neurosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that ProMIS Neurosciences share price will rise to $5.34 per share over the next 12 months.
-
What Do Analysts Say About ProMIS Neurosciences?
Analysts are divided on their view about ProMIS Neurosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ProMIS Neurosciences is a Sell and believe this share price will drop from its current level to $3.07.
-
What Is ProMIS Neurosciences's Price Target?
The price target for ProMIS Neurosciences over the next 1-year time period is forecast to be $5.34 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PMN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ProMIS Neurosciences is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PMN?
You can purchase shares of ProMIS Neurosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ProMIS Neurosciences shares.
-
What Is The ProMIS Neurosciences Share Price Today?
ProMIS Neurosciences was last trading at $0.48 per share. This represents the most recent stock quote for ProMIS Neurosciences. Yesterday, ProMIS Neurosciences closed at $0.45 per share.
-
How To Buy ProMIS Neurosciences Stock Online?
In order to purchase ProMIS Neurosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
